Aciclovir is an oral antiviral tablet for people with genital herpes, recurrent cold sores, selected varicella-zoster infections, or certain weakened-immune-state prevention needs. It is most useful when treatment begins early, and the dose is stated on the pack — follow the leaflet.
Aciclovir contains the antiviral active ingredient aciclovir, a synthetic purine nucleoside analogue. The product is supplied as tablets for oral use. The dose is stated on the pack — follow the leaflet. Aciclovir is used against herpes simplex virus type 1 and type 2, the viruses responsible for cold sores and genital herpes. It is also used in selected varicella-zoster infections, including shingles, when prescribed at an appropriate regimen.
Aciclovir contains the antiviral active ingredient aciclovir, a synthetic purine nucleoside analogue. The product is supplied as tablets for oral use. The dose is stated on the pack — follow the leaflet.
The product contains tablets for oral administration. The dose is stated on the pack — follow the leaflet. The prescribed schedule depends on the infection being treated, whether the episode is a recurrence or first outbreak, kidney function, age, and immune status.
Common clinical regimens for adults can vary:
Swallow the tablet with water. It may be taken with or without food. Maintain regular fluid intake during treatment, especially during hot weather, fever, vomiting, diarrhoea, or reduced appetite.
Do not double the next dose after a missed dose. Take the missed tablet when remembered unless the next scheduled dose is close; in that situation, skip the missed dose and continue with the usual schedule. Taking two doses together may increase adverse effects without improving antiviral activity.
The tablet should be swallowed whole unless a prescriber or pharmacist has provided a different instruction. Keep water available during the day. People with kidney disease, limited fluid intake, or a history of dehydration require extra care because aciclovir is cleared mainly through the kidneys.
Treatment should not be stopped early simply because pain or lesions improve. Incomplete courses may leave active viral replication untreated. The duration depends on the clinical indication.
After oral administration, aciclovir is converted inside infected cells into aciclovir triphosphate. Viral thymidine kinase helps initiate this activation, which gives the medicine greater activity in infected cells than in most uninfected cells.
Aciclovir triphosphate inhibits viral DNA polymerase. It also becomes incorporated into the growing viral DNA chain, where it causes chain termination. Viral DNA can no longer be copied efficiently, so the production of new herpes viruses slows.
This action explains several practical features:
Its activity depends on viral activation and renal elimination, which is why kidney function and hydration affect treatment safety [2].
The principal clinical uses include:
Aciclovir is most useful when treatment begins early. Tingling, burning, itching, blisters, or painful skin lesions may signal the beginning of an outbreak. Clinical guidance from the World Health Organization describes antiviral therapy as most helpful when started promptly during symptomatic herpes episodes [1].
Genital herpes may cause painful blisters, ulcers, burning during urination, itching, or tender groin lymph nodes. A first episode can be more extensive than later recurrences. Aciclovir may be prescribed for an initial episode, a recurrence, or suppressive treatment when outbreaks occur frequently.
People with severe first episodes may need medical assessment because dehydration, urinary retention, bacterial infection, or neurological complications can occur. Tablet treatment alone may not be sufficient for serious complications.
Cold sores usually appear on or around the lips. Early symptoms may include tingling, itching, or local burning before a blister develops. Starting oral treatment at this stage may provide greater benefit than waiting until the lesion has crusted.
Avoid touching the sore and then touching the eyes. HSV can cause serious eye infection if transferred to the cornea.
Varicella-zoster virus causes chickenpox and shingles. Aciclovir may be used in selected cases, with the dose and duration determined by the infection, age, immune status, and kidney function. A spreading rash, severe pain, eye involvement, facial weakness, or confusion needs prompt medical assessment.
Aciclovir, valaciclovir, and famciclovir belong to related antiviral treatment groups, but they differ in absorption and dosing convenience. This product contains aciclovir only.
| Active ingredient | Pharmacological difference | Typical clinical distinction |
|---|---|---|
| Aciclovir | Direct antiviral nucleoside analogue with relatively lower oral bioavailability | Often requires several daily doses |
| Valaciclovir | Prodrug converted into aciclovir after absorption | Usually permits less frequent dosing |
| Famciclovir | Prodrug converted into penciclovir | Used for selected HSV and shingles regimens |
Valaciclovir is converted into aciclovir in the body and generally reaches higher systemic exposure after oral administration. That can make its dosing schedule more convenient. Aciclovir remains a well-established option, especially when its dosing schedule is suitable and renal function has been considered.
Famciclovir uses a related but distinct active metabolite. Selection depends on the infection, previous response, kidney function, immune status, pregnancy considerations, local treatment guidance, and prescriber judgement.
These medicines are not interchangeable tablet-for-tablet. A 400 mg aciclovir tablet cannot be replaced with the same numerical strength of another antiviral ingredient.
Possible interacting medicines include other drugs that place stress on the kidneys, such as some anti-inflammatory medicines, ciclosporin, tacrolimus, and certain medicines used in cancer treatment. Probenecid and cimetidine can affect aciclovir elimination. The clinical significance depends on the complete treatment list and kidney function.
Aciclovir is not suitable for everyone. NOT for you if you have a serious allergy to aciclovir or valaciclovir, cannot maintain fluid intake, or have kidney disease requiring individual dose assessment. It requires specific medical assessment in the following situations:
Dose adjustment is often needed in renal impairment. Older adults may have reduced kidney function even when they feel well and have no known kidney diagnosis. Renal function testing can help determine the appropriate regimen.
Seek urgent care for eye pain, blurred vision, a rash near the eye, severe headache with neck stiffness, weakness, confusion, or inability to pass urine. These symptoms can indicate complications requiring more than routine oral treatment.
Many people tolerate short courses of oral aciclovir without serious problems. Reported reactions include:
Drinking enough fluid can reduce the risk of concentrated urine and kidney-related complications. Nausea may be easier to manage when the tablet is taken with a light meal, although food is not required for absorption.
Rare reactions need urgent medical attention. These include swelling of the lips or throat, breathing difficulty, widespread blistering rash, severe confusion, hallucinations, tremor, seizures, or a marked reduction in urine. Neurological reactions occur more often when aciclovir accumulates because of kidney impairment or excessive dosing.
Serious skin reactions are uncommon but require immediate treatment. Stop and seek urgent care for a rapidly spreading rash, skin peeling, mouth ulcers, or painful eye involvement.
Headache and gastrointestinal symptoms are usually mild, but persistent vomiting can cause dehydration and increase renal risk. Severe flank pain, blood in the urine, or a major reduction in urine output requires prompt assessment.
Several practical errors can reduce treatment benefit or increase risk:
One easily missed detail is that a cold sore near the eye needs urgent assessment. Rubbing the lesion and then touching the eye can transfer HSV to the cornea.
Another is the difference between symptom relief and viral clearance. Pain may settle before the infection has completed its active phase, so the prescribed schedule should be followed unless a clinician changes it.
In clinical practice, doctors often focus on timing, diagnosis, recurrence pattern, and kidney function rather than treating every herpes episode in the same way. A first genital herpes episode deserves assessment because symptoms can be extensive and another infection may resemble herpes.
For recurrent outbreaks, patients tend to obtain better symptom control when treatment starts at the first warning sign. Waiting until lesions are fully developed may reduce the benefit, especially with short treatment courses.
A prescriber may consider suppressive therapy when outbreaks are frequent, severe, distressing, or associated with substantial disruption. Suppression can reduce recurrences and viral shedding, but it does not guarantee that transmission will not occur.
A useful clinical question is whether the diagnosis has been confirmed. Recurrent genital ulcers may also arise from other infections, inflammatory disorders, trauma, or medication reactions. Persistent, atypical, or non-healing lesions need examination.
Aciclovir controls active viral replication but does not remove latent HSV from nerve tissue. Recurrences may still happen after a successful course, although treatment can shorten symptoms and reduce outbreak severity. Suppressive therapy may be considered when recurrences are frequent or severe. EMA product information describes aciclovir as treatment for herpesvirus infection rather than eradication of latent virus .
Aciclovir may be used during pregnancy when the expected benefit justifies treatment. The clinical decision depends on whether the infection is a first episode, a recurrence, or an infection close to delivery. Pregnancy-related genital herpes requires obstetric management because neonatal transmission can be serious. A 2020 ACOG practice bulletin supports antiviral management within an individual obstetric plan .
Aciclovir enters breast milk in small quantities, and treatment is often compatible with breastfeeding when clinically indicated. The infant should be observed for poor feeding, unusual sleepiness, vomiting, or diarrhoea. Extra care is needed for premature or medically fragile infants. The National Library of Medicine LactMed database records the available lactation information for aciclovir [3].
Take the missed tablet when remembered unless the next scheduled dose is close. Skip the missed dose when the next one is due soon, then resume the usual schedule. Do not take two doses together to compensate. FDA prescribing information describes this approach for missed doses and stresses dose adjustment when renal function is reduced [4].
Aciclovir can reduce viral replication and may reduce the frequency of outbreaks and viral shedding during suppressive treatment. It does not eliminate transmission risk. Avoid sexual contact during lesions or warning symptoms, and use barrier protection as advised. The effectiveness of suppression depends on adherence, the treatment plan, and the type of exposure. The 2021 Centers for Disease Control and Prevention STI Treatment Guidelines describe suppressive therapy as reducing transmission risk without eliminating it.
Urgent assessment is needed for eye pain, blurred vision, severe headache, confusion, seizures, breathing difficulty, facial swelling, a rapidly spreading rash, or very low urine output. Medical review is also needed for a first severe genital herpes episode, inability to pass urine, pregnancy with new genital lesions, or symptoms in a person with major immune suppression. These features may require examination, testing, intravenous treatment, or a different clinical approach. The 2021 Centers for Disease Control and Prevention STI Treatment Guidelines support urgent evaluation when severe or atypical features are present.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I started the tablets after the familiar tingling began. The outbreak still appeared, but the soreness settled faster than during my previous episodes. I noticed mild nausea on the first day when I took a dose without food.
The first course helped most when I started early. I kept the tablets beside my usual morning items, which made the schedule easier. The treatment did not stop later recurrences completely.
Headache and tiredness were noticeable during the first two days. They improved after I drank more water and ate regularly, but I would not describe the course as completely symptom-free.
The lesions became less painful within a few days. I had expected the tablets to prevent transmission, so I was glad the clinician explained that safer sexual practices were still needed.
